Prescient adds new members to Advisory business.
M2 PHARMA-February 13, 2020-Prescient adds new members to Advisory business
(C)2020 M2 COMMUNICATIONS
Prescient, a biopharma product and portfolio strategy firm, has added Kevin Baruzzi and Dr Arun R Shrivats to its Advisory business, it was reported on Wednesday.
Baruzzi joins as the managing director of the Boston office. He has worked in life sciences and biopharma strategy consulting, spending the better part of the last decade at ClearView Healthcare Partners. His areas of expertise and experience include opportunity assessment, disease area and indication prioritisation, clinical development strategy, target product profile design, life cycle management and competitive strategy.
Dr Shrivats is an associate director based in the company's San Francisco office. Prior to joining Prescient, he was an engagement manager at LEK Consulting following a postdoctoral fellowship at Harvard University's Wyss Institute. Shrivats' areas of expertise and experience include portfolio valuation and prioritisation, forecasting, competitive positioning, market access strategies, launch planning and commercial scale-up.
((Comments on this story may be sent to email@example.com))